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Background: Therapeutic nihilism is common in IgA nephropathy (IgAN) and renal insufficiency. Methods: 
In a randomized controlled trial comparing steroids alone or combined with azathioprine in 253 IgAN 
patients, we used a separate randomization list for patients with creatinine >2.0 mg/dL. Twenty patients 
(group 1) were randomized to 3 intravenous pulses of methylprednisolone 1 g at months 1, 3 and 5, and oral 
prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for 6 months, followed by oral 
prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further 6 months; 26 patients (group 
2) received steroids alone. The primary outcome was renal survival (50% increase in plasma creatinine from 
baseline); secondary outcomes were proteinuria over time and adverse events. Results: Six-year renal 
survival was not different between the 2 groups (50% vs. 57%; log-rank p=0.34). Median proteinuria 
decreased during follow-up in the whole population (from 2.45 g/day [interquartile range (IQR) 1.50-3.78] to 
1.09 g/day [IQR 0.56- 2.46]; p<0.001), with no between-group difference. Multivariate predictors associated 
with renal survival were sex of patient, proteinuria during follow-up, number of antihypertensive drugs, 
angiotensin-converting enzyme inhibitors and treatment including azathioprine. Six patients in group 1 
(30%) and 4 in group 2 (15%) did not complete the therapy, because of side effects (p=0.406). Conclusions: 
Six-year renal survival was similar in the 2 groups. At Cox analysis the addition of azathioprine may be 
slightly more effective than corticosteroids alone in patients with chronic renal insufficiency, although with 
an increase of side effects.  
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Introduction 
Up to 15%-20% of patients with IgA nephropathy (IgAN) reach chronic kidney disease (CKD) stage 5 
within 10 years, and up to 30%-40% within 20 years (1-3). A “point of no return,” which was defined as the 
level of serum creatinine after which IgAN inevitably progresses toward CKD stage 5, was suggested nearly 
2 decades ago (4-6). The awareness of unavoidable progression after reaching a certain stage of renal 
dysfunction has led to therapeutic nihilism, and so little is known about treatment efficacy and safety in 
patients with advanced IgAN. Corticosteroids were found to be effective in IgAN patients with plasma 
creatinine levels of ≤1.5 mg/dL and proteinuria of >1 g/day (7, 8). In 1998, we designed a randomized 
controlled trial aimed at testing whether the adding of low-dose azathioprine to steroids was more effective 
than steroids alone (9, 10). In patients with serum creatinine <2 mg/dL, adding low-dose azathioprine to 
corticosteroids for 6 months did not provide additional benefit for renal survival and proteinuria during 
follow-up and might increase the risk for adverse events (10). 
Given the lack of information about treatment in IgAN patients with CKD stages 3-4, we used a separate 
randomization list with a longer treatment course (1 year instead of 6 months) in the patients with impaired 
renal function. This paper describes the findings of this part of the trial (not included in the previous analysis 
(10)). 
 
Materials and methods  
 
Patients 
Eligible patients had to have plasma creatinine >2.0 mg/dL and proteinuria ≥1 g/day; inclusion and exclusion 
criteria are described in detail elsewhere (9, 10). 
 
Study design  
Study protocol details have been published elsewhere (10). The patients were randomly assigned to receive 
steroids plus azathioprine (group 1: intravenous methylprednisolone 1 g for 3 consecutive days at months 1, 
3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for 6 months 
followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further 6 months) 
or steroids alone with the same schedule (group 2) (clinicaltrials.gov identifier: NCT01392833). As per 
protocol, histological data were only collected from the patients who underwent renal biopsy at enrolment. 
The histological material was examined using the criteria of the World Health Organization (WHO) as 
modified by Churg and Sobin (11). 
 
Outcome measures  
The primary end point was the progression of CKD, defined as a 50% increase in serum creatinine from 
baseline (to be confirmed 1 month later). The secondary end points were the evolution of proteinuria over 
time and adverse events. 
 
Statistical analysis  
For descriptive purposes, mean values and standard deviations were used for the normally distributed 
continuous variables, median values and interquartile ranges (IQRs) for the skewed continuous variables, and 
absolute numbers for the categorical variables. Cumulative renal survival without reaching the end point of a 
50% increase in baseline creatinine was calculated using the Kaplan-Meier method, and the 2 treatment 
groups were compared on an intention-to-treat basis, using the log-rank test. Multivariate Cox regression 
analysis was used to estimate the effect of the experimental treatment, adjusted for some possibly prognostic 
covariates. The explanatory covariates of the final model were selected using a backward stepwise method. 
The assumption of constant hazard rates over time was checked by means of plots of the logarithm of the 
survival function against time. All of the analyses were made using SPSS statistical software for Windows, 




Patient characteristics  
 
Trial enrolment began in December 1999 and closed in November 2005. Forty-six out of 253 patients (10) 
were included in this separate randomization list: 20 patients were assigned to steroids plus azathioprine 
(group 1) and 26 to steroids alone (group 2) (Fig. 1). At baseline, the 2 groups were similar for age, sex, 
duration of IgAN, serum creatinine levels and systolic and diastolic blood pressure. Median proteinuria was 
higher in group 1 than in group 2 (3.2 vs. 2.0 g/day; p=0.020) (Tab. I). Renal biopsy was performed after a 
median of 0.17 years (IQR 0.02-5.58 years). Histological evaluation of the 23 patients undergoing biopsy at 
enrolment showed renal lesions consistent with grade III of the Churg and Sobin classification (13); none of 
the patients showed signs of rapidly progressive glomerulonephritis. 
 
Antihypertensive therapy and renin-angiotensin system blockade  
 
At baseline, nearly all of the patients (43/46; 94%) were hypertensive. Blood pressure values were similar in 
groups 1 and 2 at baseline (135.5 ± 17.1 / 80.7 ± 10.0 mm Hg vs. 135.0 ± 18.3 / 83.0 ± 11.9 mm Hg) and 
during the follow-up (135.4 ± 15.8 / 84.0 ± 8.0 mm Hg vs. 135.0 ± 11.8 / 84.0 ± 5.1 mm Hg). The majority 
of the patients were already being treated with angiotensin-converting enzyme inhibitors (ACEIs) and/or 
angiotensin receptor blockers (ARBs) (85.0% in group 1 and 84.6% in group 2). Among the 7 patients who 
were not being treated with renin-angiotensin system (RAS) blockade at baseline, only 1 started an ACEI 
during followup (group 1). 
 
Renal survival  
The patients were followed up for a median of 4.5 years (IQR 2.9-6.1). At intention-to-treat analysis, 10 
patients (50%) in group 1 and 11 (42%) in group 2 reached the primary end point of a 50% increase of serum 
creatinine; 6-year end point–free renal survival was not statistically different between the 2 groups (50% and 
57%; log-rank p=0.34) (Fig. 2). Nine patients in group 1 (45%) and 10 in group 2 (39%) started dialysis after 
a median follow-up of 4.0 years (IQR 2.2-4.8 years) (p=0.81). Similar results were obtained using the per-
protocol analysis of the 35 patients who completed the 12-month treatment. 
 
Proteinuria  
Median proteinuria decreased significantly during follow-up in the population as a whole from 2.45 g/day 
(IQR 1.50-3.78) to 1.25 g/day (IQR 0.54-2.43) (p<0.001), with no significant difference between the 2 
groups (p=0.634) (Fig. 3). In group 1, it decreased from 3.20 g/day (IQR 1.74-5.54) to 2.73 g/day (IQR 0.82-
4.13) (a reduction of 0.43 g/day), and in group 2 from 2.00 g/day (IQR 1.50-3.23) to 1.05 g/day (IQR 0.53-
1.47) (a reduction of 0.95 g/day). Eighteen patients (39%) reached a mean proteinuria <1 g/day during 
follow-up, with no statistical difference between the 2 groups (p=0.364). Given the initial random imbalance 
at baseline, proteinuria 
was significantly higher in group 1 than in group 2 at the various follow-up time points (p<0.001) (Fig. 3). 
 
 
Multivariate Cox regression analysis  
The risk of reaching the primary end point was 91% lower among women, 4.6 times higher for each gram of 
proteinuria during follow-up, 55% lower for each antihypertensive drug taken during follow-up, 79% lower 
in the patients who received an ACEI, and 92% lower in the patients who received the experimental 
treatment (Tab. II). Serum creatinine, proteinuria and the number of antihypertensive drugs taken at baseline 
had no independent effect on the risk of reaching the end point. Side effects Ten of the 46 randomized 
patients (6 in group 1 and 4 in group 2) did not complete the 12 months of therapy, because of side effects 
(p=0.406) (Tab. III). One patient in group 1 withdrew from the study because he was transferred to another 
center after 6 months. 
 
Discussion  
In IgAN patients with serum creatinine levels of >2 mg/dL, we found no benefit for renal survival with the 
addition of azathioprine to steroids in comparison with steroids alone at primary analysis. Both treatment 
schedules obtained a significant reduction of proteinuria during follow-up, without any between-group 
difference. As there was no control group of untreated patients, we are unable to demonstrate that the 
reduction in proteinuria was accompanied by a significant reduction in the risk of reaching end-stage renal 
disease (ESRD). In contrast with univariate analysis, multivariate Cox regression analysis showed that the 
addition of azathioprine was an independent factor favorably affecting patient outcome. This discrepancy 
may be due to the fact that the patients in group 1 had higher proteinuria levels at baseline and during follow-
up (Fig. 3), possibly masking a benefit of the addition of azathioprine. However, given the small sample size 
of this randomization list and the fact that renal survival at log-rank test was not different in the 2 treatment 
groups, great caution is needed in interpreting these findings. The median baseline serum creatinine levels in 
our patients were similar to those in the patients described in papers concerning the “point of no return” (4, 
5). With all of the limitations of historical comparisons, these untreated patients experienced a much faster 
progression of their nephropathy compared with those of the present study. This indirectly suggests that both 
immunosuppressive regimens (steroids alone or combined with azathioprine) may slow progression to ESRD 
even in patients with more advanced disease. Although its effect was not significant (p=0.406; Tab. III), 
adding azathioprine to steroids numerically increased the risk of drug-related adverse events causing 
premature treatment discontinuation (30% vs. 15%). The higher withdrawal rate among the patients 
receiving azathioprine may have decreased the likelihood of observing its possible beneficial effects, but the 
results of the per-protocol analysis were comparable with those of the intention-to-treat analysis.  
Only a few other studies have evaluated immunosuppressive therapy in IgAN patients with CKD stages 3-4. 
The majority were retrospective and enrolled patients with more preserved renal function than ours. 
Moreover, their treatment schedules were not comparable in terms of the drugs used, their doses or treatment 
duration, and none compared 2 different immunosuppressive drug regimens. Goumenos et al (14) 
retrospectively evaluated 114 patients (61 with baseline renal impairment defined as serum creatinine levels 
of >1.24 mg/dL) and found that, after a follow-up of 46 months, 79% of the patients receiving steroids plus 
azathioprine had stable renal function but only 36% of the untreated patients. However, the same authors 
were not able to confirm their positive findings in another retrospective study of 74 patients observed for a 
longer follow-up period (15), although the patients with severe proteinuria seemed to benefit more from the 
combination, which was given at higher doses and for a longer period than in our study. Mitsuiki et al (16) 
retrospectively investigated 35 patients with histologically advanced IgAN: 27 received prednisolone for 
more than 2 years and cyclophosphamide for 6 months, and 8 received supportive treatment alone. After 5 
years, all of the patients in the control group had developed CKD stage 5, whereas the majority of the treated 
patients were still free of dialysis. Treatment-related side effects were observed in only 2 patients. Roccatello 
et al (17) obtained favorable results with a combined schedule of steroids and mycophenolate mofetil in a 
subset of IgAN patients. However, patient characteristics were not comparable with our population, since all 
of the patients had at least 10% florid crescents. Ballardie and Roberts (18) performed the only prospective, 
randomized study, in which 38 patients with progressive IgAN received prednisolone 40 mg/day (reduced to 
10 mg/day after 2 years) with cyclophosphamide 1.5 mg/kg per day for the first 3 months, followed by the 
same dose of azathioprine for a minimum of 2 years, or supportive therapy alone. The treated patients 
experienced significantly better renal survival and a greater reduction in proteinuria levels than those in the 
control group. Despite the fact that the azathioprine dose was the same as that used in our trial and it was 
given for longer, the rate of drug-related side effects was lower. This may be partially due to the fact that we 
enrolled patients with more advanced CKD. Given that only 23 out of 46 patients underwent kidney biopsy 
at enrolment, we cannot exclude that some patients presenting fresh lesions were together with cases with 
sclerotic ones, possibly limiting the favorable effect of azathioprine. 
Finally, our multivariate Cox analysis showed that ACEI had an independent beneficial effect on renal 
survival. This is in line with the results of a clinical trial indicating that steroids plus ACEIs preserve renal 
function better than ACEIs alone in IgAN patients with normal renal function (19), and the findings of Hou 
et al (20), which indicate that ACEIs also have a renoprotective effect in patients with advanced renal 
insufficiency of various etiology. As the use of RAS blockers was equally distributed in our 2 groups, it is 
unlikely that this influenced the study results. In brief, the 6-year renal survival at log-rank test was similar in 
the 2 groups. The Cox analysis might suggest that the addition of azathioprine may be slightly more effective 
than corticosteroids alone in patients with CKD stages 3-4, although associated with an increased risk of side 
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TABLE I.  BASELINE CLINICAL AND LABORATORY CHARACTERISTICS BY TREATMENT GROUP 
 
 Fig. 2 - Kaplan-Meier renal survival curves estimated on the basis of the time to a 50% increase in serum 
creatinine levels (p value from the log-rank test). Aza = azathioprine. 
 
Fig. 3 - Urinary protein excretion at baseline and during follow-up in the 2 treatment groups. The lines 
crossing the boxes indicate the median value, and the boxes the interquartile range containing 50% of the 
values; the whiskers show the highest and lowest values that are less than 1.5 box lengths from the 25th or 
75th centile. The circles and asterisks indicate more extreme values (outliers). Aza = azathioprine. 
 
TABLE II 




 TABLE III SIDE EFFECTS AND OTHER CLINICAL EVENTS BY TREATMENT GROUP 
 
